絞り込み

16599

広告

3018件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

[Asthma of difficult control linked to pulmonary thromboembolism and bronchopulmonary aspergillosis].

Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants.

Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants?

A Comparative Analysis of the Safety Profile of Direct Oral Anticoagulants Using the FDA Adverse Event Reporting System.

Bleeding Incidence and Risk Factors among Cancer Patients Treated with Anticoagulation.

Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016.

Dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A Danish nationwide cohort study.

Apixaban versus warfarin in evaluation of progression of atherosclerotic and calcified plaques (prospective randomized trial).

Low molecular weight heparin and direct oral anticoagulants influence tumour formation, growth, invasion and vascularisation by separate mechanisms.

Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation.

Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review protocol.

Classification and characteristics of on-label and off-label apixaban use in Denmark and Sweden.

Resuming Anticoagulation following Upper Gastrointestinal Bleeding among Patients with Nonvalvular Atrial Fibrillation-A Microsimulation Analysis.

An assay to measure levels of factor Xa inhibitors in blood and plasma.

Meta-Analysis of Direct-Acting Oral Anticoagulants Compared With Warfarin in Patients >75 Years of Age.

Safety of Apixaban Administered via Nasogastric Tube.

Ritonavir- or cobicistat-boosted antiretroviral therapy and direct oral anticoagulants: A case for apixaban.

Andexanet alfa for the reversal of factor Xa inhibitors.

Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.

Consensus in cardiology on non-vitamin k oral anticoagulants for patients with atrial fibrillation.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります